[go: up one dir, main page]

EA201171062A1 - Алкиламидные соединения и их применение - Google Patents

Алкиламидные соединения и их применение

Info

Publication number
EA201171062A1
EA201171062A1 EA201171062A EA201171062A EA201171062A1 EA 201171062 A1 EA201171062 A1 EA 201171062A1 EA 201171062 A EA201171062 A EA 201171062A EA 201171062 A EA201171062 A EA 201171062A EA 201171062 A1 EA201171062 A1 EA 201171062A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
hydrogen
group
compounds
alkilamide
Prior art date
Application number
EA201171062A
Other languages
English (en)
Other versions
EA020198B1 (ru
Inventor
Серджо Барони
Сальваторе Беллинвия
Франческа Вити
Original Assignee
Джулиани Интернэшнл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джулиани Интернэшнл Лимитед filed Critical Джулиани Интернэшнл Лимитед
Publication of EA201171062A1 publication Critical patent/EA201171062A1/ru
Publication of EA020198B1 publication Critical patent/EA020198B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)

Abstract

Описанными в настоящем изобретении являются соединения формулы (I), которые могут быть специфичными по отношению к PPAR и/или EGF рецепторам, и способы их получения и применения, в которых Х представляет собой C-Салкилен, необязательно замещенный одним, двумя или тремя заместителями, выбранными из галогена или гидроксила; Rвыбирают из группы, состоящей из C-Салкила, С-Сциклоалкила, С-Салкенила и С-Салкинила; Rвыбирают из группы, состоящей из водорода и C-Салкила; Rнезависимо выбирают для каждого случая из группы, состоящей из водорода, C-Салкокси, C-Салкила, циано, С-Сциклоалкила, галогена, гидроксила и нитро; Rвыбирают из группы, состоящей из водорода и C-Салкила; Rпредставляет собой водород и C-Салкил; или их фармацевтически приемлемые соли или N-оксиды.
EA201171062A 2009-02-16 2010-02-16 N-ацетил-(r)-(-)-3-(4-аминофенил)-2-метоксипропионовая кислота, содержащая ее фармацевтическая композиция, способ лечения EA020198B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09425056 2009-02-16
US17906209P 2009-05-18 2009-05-18
US28746109P 2009-12-17 2009-12-17
PCT/EP2010/000935 WO2010091892A2 (en) 2009-02-16 2010-02-16 Alkylamido compounds and uses thereof

Publications (2)

Publication Number Publication Date
EA201171062A1 true EA201171062A1 (ru) 2012-01-30
EA020198B1 EA020198B1 (ru) 2014-09-30

Family

ID=42562114

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201171062A EA020198B1 (ru) 2009-02-16 2010-02-16 N-ацетил-(r)-(-)-3-(4-аминофенил)-2-метоксипропионовая кислота, содержащая ее фармацевтическая композиция, способ лечения
EA201171063A EA020856B1 (ru) 2009-02-16 2010-02-16 Способы лечения патологических состояний, связанных с волосами

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201171063A EA020856B1 (ru) 2009-02-16 2010-02-16 Способы лечения патологических состояний, связанных с волосами

Country Status (25)

Country Link
US (11) US8796334B2 (ru)
EP (4) EP3744398A1 (ru)
JP (4) JP5645851B2 (ru)
KR (2) KR101776337B1 (ru)
CN (3) CN104666288B (ru)
AR (1) AR080596A1 (ru)
AU (2) AU2010213093B2 (ru)
BR (2) BRPI1011226B1 (ru)
CA (2) CA2752623C (ru)
CY (2) CY1119225T1 (ru)
DK (2) DK2396081T3 (ru)
EA (2) EA020198B1 (ru)
ES (3) ES2429143T3 (ru)
HR (2) HRP20170936T1 (ru)
HU (2) HUE032999T2 (ru)
IL (2) IL214665A (ru)
LT (2) LT2805746T (ru)
MX (3) MX381002B (ru)
NZ (2) NZ595080A (ru)
PL (1) PL2396081T3 (ru)
PT (3) PT2396082E (ru)
SI (2) SI2396081T1 (ru)
UA (2) UA109525C2 (ru)
WO (2) WO2010091894A2 (ru)
ZA (1) ZA201106256B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4805556A (en) 1988-01-15 1989-02-21 Union Carbide Corporation Reactor system and method for forming uniformly large-diameter polycrystalline rods by the pyrolysis of silane
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
AU2010213093B2 (en) 2009-02-16 2016-01-07 Nogra Pharma Limited Alkylamido compounds and uses thereof
ES2711100T3 (es) 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
CN109999017A (zh) * 2012-02-09 2019-07-12 诺格拉制药有限公司 治疗纤维化的方法
NZ631049A (en) 2012-04-18 2017-02-24 Nogra Pharma Ltd Methods of treating lactose intolerance
PL2895160T3 (pl) * 2012-09-13 2018-09-28 Nogra Pharma Limited Sposoby leczenia stanów związanych z włosami
CN104736149A (zh) * 2012-09-13 2015-06-24 诺格拉制药有限公司 抑制毛发生长的方法
KR101441278B1 (ko) * 2013-11-17 2014-09-17 한규나 머리카락 분말을 이용한 재활용 방법
JP6371520B2 (ja) * 2013-12-26 2018-08-08 日本メナード化粧品株式会社 皮脂合成促進剤
JP2018517665A (ja) 2015-04-06 2018-07-05 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 哺乳動物対象における皮膚色素沈着を減少させるかまたはその増加を予防するかもしくは逆転させるための組成物および方法
WO2017210600A1 (en) * 2016-06-03 2017-12-07 The Scripps Research Institute Compositions and methods of modulating immune response
US20220000818A1 (en) * 2019-01-25 2022-01-06 Nogra Pharma Limited Compositions for use in preventing acne
SMT202500054T1 (it) * 2019-02-08 2025-03-12 Nogra Pharma Ltd Processo per produrre acido 3-(4'-amminofenil)-2-metossipropionico, e relativi analoghi e intermedi
JP6925072B1 (ja) * 2020-12-07 2021-08-25 株式会社Dr.Cherry 毛髪改善のための組成物

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) * 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en) 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en) 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en) 1972-02-25 1974-07-10 Merck & Co Inc Preparation of pyrrylsalicylic acid
US4036951A (en) 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr) 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
US4348223A (en) 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
DE3164618D1 (en) 1980-12-22 1984-08-09 Schering Ag 3-substituted 2,4,6-trihalogenobenzamides and their salts, their preparation and their use as substitutes for natural sweetening agents, and sweeteners containing them
JPS58194814A (ja) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
IL69282A (en) 1982-09-02 1988-06-30 Euro Celtique Sa Method for the carboxylation of potassium phenoxide with carbon dioxide
GB8302708D0 (en) 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
DE3786452T2 (de) 1987-02-05 1993-10-21 Kureha Chemical Ind Co Ltd Benzylether-Verbindungen und Verfahren zu ihrer Herstellung.
NZ224087A (en) 1987-04-01 1990-08-28 Dak Lab As Topical pharmaceutical compositions containing 4- or 5- amino salicylic acid or a functional derivative thereof
DE68919009T2 (de) 1988-05-05 1995-02-23 Tillotts Pharma Ag Verwendung von 5-Amino-salicylsäure für die Behandlung von Hautkrankheiten.
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
ATE256468T1 (de) 1990-10-22 2004-01-15 Gastro Services Pty Ltd Behandlung von nicht-entzündlichen darmerkrankungen
US5262549A (en) 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en) 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
DE69331414T2 (de) 1992-03-17 2002-08-08 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide, herstellung und anwendung
CA2120367C (en) 1992-06-30 2004-05-11 Howard K. Shapiro Compositions and use of pharmaceutical compositions in the treatment of symptoms of disorders related to chronic inflammatory diseases and etiologically related symptomology
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
CA2190107A1 (en) 1994-05-11 1995-11-23 Howard K. Shapiro Compositions for treatment of chronic inflammatory diseases
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
CA2215160A1 (en) 1995-03-28 1996-10-03 Maria-Helena Joris Jozef Verlinden Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
AU6773598A (en) 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
WO1999015520A1 (fr) 1997-09-19 1999-04-01 Ono Pharmaceutical Co., Ltd. Composes de benzene fusionnes ou non fusionnes
US7015249B1 (en) 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US20040034067A1 (en) 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6369098B1 (en) 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US7736661B1 (en) 2000-03-07 2010-06-15 Avon Products, Inc Method of treating skin conditions
DE60013491T2 (de) 2000-04-19 2005-09-01 Neurotech Co., Ltd., Suwon Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
ES2312432T3 (es) * 2000-05-29 2009-03-01 Kyorin Pharmaceutical Co., Ltd. Derivados del acido fenilpropionico sustituidos.
AU8531101A (en) 2000-08-29 2002-03-13 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
JPWO2002046161A1 (ja) * 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
FR2822955B1 (fr) 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
WO2002085123A1 (en) 2001-04-18 2002-10-31 Merck & Co., Inc. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
CA2354921A1 (en) 2001-05-24 2002-11-24 Yasuo Konishi Drug evolution: drug design at hot spots
IL161429A0 (en) 2001-10-16 2004-09-27 Reddys Lab Ltd Dr Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing the same
AU2002357729A1 (en) 2001-11-16 2003-06-10 Nutrition 21, Inc. Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
WO2003045383A1 (en) 2001-11-26 2003-06-05 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
WO2003053974A1 (en) 2001-12-21 2003-07-03 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US8492438B2 (en) 2002-04-26 2013-07-23 Asan Laboratories Company (Cayman), Limited Treatment skin disorders
AU2003228744A1 (en) 2002-04-29 2003-11-17 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
CA2527861A1 (en) 2003-07-21 2005-02-10 Applied Research Systems Ars Holding N.V. Alkynyl aryl carboxamides
UA60954C2 (en) 2003-07-25 2006-03-15 Subsidiary Entpr With Foreign Method for measuring conductivity of electrolyte by a contactless measuring transducer
WO2005039590A1 (en) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
EP1680397A2 (en) 2003-10-28 2006-07-19 Dr. Reddy's Laboratories Ltd. Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
FR2862870A1 (fr) 2003-12-01 2005-06-03 Galderma Res & Dev Utilisation d'activateurs de recepteurs ppar en cosmetique et dermatologie.
JP2007513173A (ja) 2003-12-03 2007-05-24 スミスクライン・ビーチャム・コーポレイション ロシグリタゾンを用いる乾癬の治療
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
WO2005084658A1 (en) * 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20050277693A1 (en) 2004-06-10 2005-12-15 Dr. Reddy's Laboratories Limited Basic salts and monohydrates of certain alpha, beta-propionic acid derivative
PE20060594A1 (es) 2004-09-09 2006-08-18 Novartis Ag Composicion farmaceutica que contiene un agonista de ppar
EP1799866A4 (en) 2004-09-27 2010-12-01 Us Gov Health & Human Serv MODULATION OF MXA EXPRESSION
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
EP1719543A1 (en) 2005-05-04 2006-11-08 Asan Labs., Ltd. Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de) 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en) 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US8796282B2 (en) 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
US20090054312A1 (en) 2007-08-22 2009-02-26 Wolf Dieter A SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en) 2008-03-31 2011-10-04 Saltigo Gmbh Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
AU2010213093B2 (en) 2009-02-16 2016-01-07 Nogra Pharma Limited Alkylamido compounds and uses thereof
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
WO2013012662A2 (en) 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
WO2013059364A2 (en) 2011-10-17 2013-04-25 The Regents Of The University Of California Methods for assessing repellant quality of organic materials and methods and compositions for repelling arthropods
ES2602075T3 (es) 2011-10-31 2017-02-17 Larsen, Claus Selch Profármacos de agentes antiinflamatorios no esteroideos (AINE)
CN109999017A (zh) 2012-02-09 2019-07-12 诺格拉制药有限公司 治疗纤维化的方法
NZ631049A (en) 2012-04-18 2017-02-24 Nogra Pharma Ltd Methods of treating lactose intolerance
JP6096179B2 (ja) 2012-05-10 2017-03-15 国立大学法人岩手大学 ラクターゼ活性を有するタンパク質、該タンパク質をコードする遺伝子、該遺伝子を含有する組み換えベクター、形質転換体、及びその製造方法並びに用途
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
CN104619687A (zh) 2012-06-01 2015-05-13 诺格拉制药有限公司 能够调节t-细胞应答的双环杂环及其使用方法
CA2875964C (en) 2012-06-07 2018-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
PL2895160T3 (pl) 2012-09-13 2018-09-28 Nogra Pharma Limited Sposoby leczenia stanów związanych z włosami
CN104736149A (zh) 2012-09-13 2015-06-24 诺格拉制药有限公司 抑制毛发生长的方法
PL2978416T3 (pl) 2013-03-26 2017-03-31 Lipid Therapeutics Gmbh Formulacja farmaceutyczna zawierająca fosfatydylocholinę do leczenia wrzodziejącego zapalenia jelita grubego
CN105566153B (zh) 2014-10-14 2019-05-31 中国医学科学院药物研究所 偶氮苯衍生物及其制法和药物组合物与用途
US20180193361A1 (en) 2015-04-02 2018-07-12 University Health Network Gut anti-inflammatory agents for regulation of high blood glucose levels
HK1252978A1 (zh) 2015-06-15 2019-06-06 Nmd Pharma Aps 用於治療神經肌肉病癥的化合物
WO2017046343A1 (en) 2015-09-17 2017-03-23 Nogra Pharma Limited Compositions for rectal administration in the treatment of ulcerative colitis and methods of using same
WO2017093444A1 (en) 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
EP3419616A1 (en) 2016-02-26 2019-01-02 Nogra Pharma Limited Methods of treating lactose intolerance

Also Published As

Publication number Publication date
NZ595080A (en) 2013-09-27
US20170172956A1 (en) 2017-06-22
MX2011008602A (es) 2011-09-09
EP2396082A2 (en) 2011-12-21
US10959970B2 (en) 2021-03-30
LT2805746T (lt) 2020-09-25
PL2396081T3 (pl) 2017-10-31
IL214665A0 (en) 2011-09-27
CA2752623C (en) 2017-07-04
HRP20170936T1 (hr) 2017-09-22
US9901557B2 (en) 2018-02-27
WO2010091894A2 (en) 2010-08-19
US10398667B2 (en) 2019-09-03
DK2805746T3 (da) 2020-08-10
EA201171063A1 (ru) 2012-01-30
US20120053244A1 (en) 2012-03-01
HUE050267T2 (hu) 2020-11-30
BRPI1008752A2 (pt) 2016-03-08
SI2805746T1 (sl) 2020-10-30
ES2630044T3 (es) 2017-08-17
CN104666288B (zh) 2017-08-04
EP2805746B1 (en) 2020-05-06
ZA201106256B (en) 2012-05-30
KR101776337B1 (ko) 2017-09-07
US20120053245A1 (en) 2012-03-01
US20200188340A1 (en) 2020-06-18
WO2010091892A2 (en) 2010-08-19
CN102316932B (zh) 2014-07-09
HUE032999T2 (hu) 2017-11-28
UA105037C2 (ru) 2014-04-10
US20220354809A1 (en) 2022-11-10
KR20110120946A (ko) 2011-11-04
JP2014237692A (ja) 2014-12-18
JP5645851B2 (ja) 2014-12-24
ES2429143T3 (es) 2013-11-13
IL214665A (en) 2017-02-28
EP2396081B1 (en) 2017-04-05
HRP20201184T1 (hr) 2020-12-11
AR080596A1 (es) 2012-04-25
IL214664A (en) 2015-09-24
US10137101B2 (en) 2018-11-27
AU2010213095B2 (en) 2015-09-17
WO2010091892A3 (en) 2010-10-21
SI2396081T1 (sl) 2017-09-29
JP2015155427A (ja) 2015-08-27
CY1123213T1 (el) 2021-12-31
ES2806691T3 (es) 2021-02-18
BRPI1008752B1 (pt) 2020-02-11
PT2805746T (pt) 2020-08-17
PT2396082E (pt) 2013-10-03
IL214664A0 (en) 2011-09-27
MX2011008601A (es) 2011-09-09
US20160338927A1 (en) 2016-11-24
LT2396081T (lt) 2017-09-11
US8796334B2 (en) 2014-08-05
CN102316932A (zh) 2012-01-11
EP3744398A1 (en) 2020-12-02
AU2010213093B2 (en) 2016-01-07
BRPI1011226A2 (pt) 2016-03-15
EA020856B1 (ru) 2015-02-27
BRPI1011226B1 (pt) 2019-10-29
MX381002B (es) 2025-03-12
US20190269637A1 (en) 2019-09-05
US8754127B2 (en) 2014-06-17
EA020198B1 (ru) 2014-09-30
KR101800901B1 (ko) 2017-11-23
UA109525C2 (xx) 2015-09-10
JP2012517968A (ja) 2012-08-09
US20180369178A1 (en) 2018-12-27
JP5820030B2 (ja) 2015-11-24
PT2396081T (pt) 2017-07-11
WO2010091894A3 (en) 2010-11-11
CN102316931A (zh) 2012-01-11
US20150051285A1 (en) 2015-02-19
EP2396081A2 (en) 2011-12-21
KR20110120945A (ko) 2011-11-04
EP2805746A1 (en) 2014-11-26
JP2012517969A (ja) 2012-08-09
CA2752626A1 (en) 2010-08-19
NZ595076A (en) 2013-09-27
EP2396082B1 (en) 2013-07-31
AU2010213095A1 (en) 2011-09-08
DK2396081T3 (en) 2017-07-10
US20200383942A1 (en) 2020-12-10
CA2752626C (en) 2018-03-27
CA2752623A1 (en) 2010-08-19
US9511041B2 (en) 2016-12-06
AU2010213093A1 (en) 2011-09-08
CN104666288A (zh) 2015-06-03
CY1119225T1 (el) 2018-02-14
JP5715070B2 (ja) 2015-05-07
CN102316931B (zh) 2014-11-19
US20150148418A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
EA201171062A1 (ru) Алкиламидные соединения и их применение
EP2597088A4 (en) P2X4 Receptor Antagonists
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
CO6640226A2 (es) 5-fluoro-1h-pirazolipiridinas sustituidas y su uso
MX382352B (es) Compuestos de heteroarilo y usos de los mismos.
CY1118004T1 (el) Αναστολεις cdk
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
CR20140135A (es) Nuevos derivados de aril-quinolina
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
UY32296A (es) Nuevos compuestos
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
EA201500875A1 (ru) СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2-(1Н)-ОНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
CR20120643A (es) Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica
EA201590023A1 (ru) Новые 4-замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
RS54183B1 (en) PIRAZOLE DERIVATIVES
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
EA201101097A1 (ru) Новые микробиоциды
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM